Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

5.26
+0.15002.94%
Volume:545.42K
Turnover:2.81M
Market Cap:164.59M
PE:-1.27
High:5.28
Open:5.06
Low:5.01
Close:5.11
52wk High:50.40
52wk Low:4.54
Shares:31.29M
Float Shares:18.39M
Volume Ratio:1.02
T/O Rate:2.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.75
PE(LYR):-1.85

Loading ...

Eledon Therapeutics: Buy Rating Reaffirmed on Strong Cash Runway and Tegoprubart Data; Price Target Unchanged at $8

TIPRANKS
·
Aug 14

HighTide Therapeutics Sets Board Meeting to Approve Interim Results

TIPRANKS
·
Aug 14

TenNor Therapeutics Sets Board Meeting to Review Interim Results and Possible Dividend

TIPRANKS
·
Aug 14

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings
·
Aug 14

Percheron Therapeutics Adds New Shares to ASX Quotation

TIPRANKS
·
Aug 14

Modalis Therapeutics Issues Further Corrections to Interim Financial Results

TIPRANKS
·
Aug 14

PYC Therapeutics boosts CEO equity incentives with major option and rights grants

TIPRANKS
·
Aug 14

Silexion Therapeutics Executes Reverse Share Split Amid Strain

TIPRANKS
·
Aug 14

Tempest Therapeutics Secures Flexible $50 Million Equity Facility

TIPRANKS
·
Aug 14

Silexion Therapeutics Closes Public Offering and Strengthens Equity

TIPRANKS
·
Aug 14

Serina Therapeutics Q2 EPS $(0.55) Misses $(0.47) Estimate, Sales $130.000K, Same YoY

Benzinga Earnings
·
Aug 14

Cadrenal Therapeutics Q2 EPS $(1.14) Beats $(1.42) Estimate

Benzinga Earnings
·
Aug 14

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

GlobeNewswire
·
Aug 14

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 14

Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position

TIPRANKS
·
Aug 14

Obsidian Therapeutics Down over 21%, on Pace for Largest Percent Decrease Since October 2024

Dow Jones
·
Aug 14

Ovid Therapeutics: Buy Rating Backed by De-Risked Balance Sheet and Differentiated Epilepsy Pipeline (OV329, OV4071)

TIPRANKS
·
Aug 14

Enliven Therapeutics (ELVN) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
Aug 13

Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says

MT Newswires Live
·
Aug 13

HLS Therapeutics Earns Reiterated Buy Rating from David Martin on Strong 2Q Results and Clozaril Recovery; C$12 Price Target Maintained

TIPRANKS
·
Aug 13